These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 30670436

  • 1. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.
    Kebriaei R, Rice SA, Stamper KC, Rybak MJ.
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [Abstract] [Full Text] [Related]

  • 2. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR, Yim J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.
    Xhemali X, Smith JR, Kebriaei R, Rice SA, Stamper KC, Compton M, Singh NB, Jahanbakhsh S, Rybak MJ.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):82-86. PubMed ID: 30260409
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ, Barber KE, Ireland CE, Rybak MJ.
    Antimicrob Agents Chemother; 2014 Jun 01; 58(6):3177-81. PubMed ID: 24663016
    [Abstract] [Full Text] [Related]

  • 5. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C, Leonard SN, Rybak MJ.
    Int J Antimicrob Agents; 2010 Jun 01; 35(6):527-30. PubMed ID: 20346632
    [Abstract] [Full Text] [Related]

  • 6. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
    Werth BJ, Ashford NK, Penewit K, Waalkes A, Holmes EA, Ross DH, Shen T, Hines KM, Salipante SJ, Xu L.
    Clin Microbiol Infect; 2021 Jun 01; 27(6):910.e1-910.e8. PubMed ID: 32866650
    [Abstract] [Full Text] [Related]

  • 7. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
    Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ.
    Antimicrob Agents Chemother; 2013 Jan 01; 57(1):66-73. PubMed ID: 23070161
    [Abstract] [Full Text] [Related]

  • 8. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep 01; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Aug 01; 59(8):4497-503. PubMed ID: 25987623
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS, Flamm RK, Jones RN.
    Antimicrob Agents Chemother; 2013 Jul 01; 57(7):3178-81. PubMed ID: 23629712
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
    Werth BJ, Steed ME, Kaatz GW, Rybak MJ.
    Antimicrob Agents Chemother; 2013 Jun 01; 57(6):2664-8. PubMed ID: 23545533
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2011 Jul 01; 55(7):3522-6. PubMed ID: 21576449
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
    Vidaillac C, Leonard SN, Rybak MJ.
    Antimicrob Agents Chemother; 2009 Nov 01; 53(11):4712-7. PubMed ID: 19738009
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
    Kebriaei R, Rice SA, Singh NB, Stamper KC, Nguyen L, Sheikh Z, Rybak MJ.
    J Antimicrob Chemother; 2020 Oct 01; 75(10):2894-2901. PubMed ID: 32591820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.